DOCSLIB.ORG

Anxiety and Substance Use Disorders: a Primer for Primary Care Physicians

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Anxiety and Substance Use Disorders: a Primer for Primary Care Physicians J Am Board Fam Pract: first published as 10.3122/jabfm.4.1.47 on 1 January 1991. Downloaded from Anxiety And Substance Use Disorders: A Primer For Primary Care Physicians MimI Landry, David E. Smith, M.D., David McDuff, M.D., and Otis 1. Baughman III, M.D. Abstract: Primary care physicians encounter many patients with primary and secondary anxiety and substance use problems. Some patients have a dual diagnosis of both an anxiety and a substance use disorder. Symptoms may be overdiagnosed, underdiagnosed, and misdiagnosed. This article provides the primary care physician with an overview of the relation between psychoactive substance use disorders and anxiety symptoms. Also described are drug use patterns and diagnostic criteria for psychoactive substance use disorders. A model for understanding the role of anxiety symptoms during drug use is provided. (J Am Board Fam Pract 1991; 4:47-53.) Primary care physicians, especially rural family abuse liability, and dual or multiple diagnoses, physicians, often are the first practitioners to see all within the practical time constraints of pa­ patients who have maladaptive drug use or psy­ tient visits. chiatric problems. In particular, primary care Physicians and other professionals who focus physicians treat many patients who have anxiety their work on the treatment of addictions have disorders, the most prevalent group of psychiat­ become aware of the complex interrelations ric conditions in the United States. I Indeed, among common psychiatric syndromes, espe­ physicians in family practice, general practice, cially the forms of anxiety; substance use and internal medicine, and osteopathy write two abuse, especially alcohol, illicit drugs, and pre­ thirds (66.8 percent) of all new prescriptions for scribed medications; and ordinary medical ill­ antianxiety or anxiolytic medications.2 They pre­ nesses. These increasingly common clinical scribe anxiolytics more frequently than psychi­ problems can coexist in the same patient, mimic atrists-who prescribe more antidepressants each other, and mask or exacerbate each other. than primary care physicians-however, psychi­ Modem clinicians, especially those in primary atrists typically provide a mental illness diagnosis care specialties, must become expert in the fine http://www.jabfm.org/ for these patients while primary care physicians points of recognition, the subtleties of diagnosis, typically do not.3 Concurrently, primary care the risks and benefits of prescribing psychoactive clinicians treat large numbers of patients with medications, and the art of obtaining effective substance use disorders, whose complaints often consultations and making appropriate referrals. are anxiety, insomnia, or depression, rather than This article focuses on the subtleties of diag­ substance use. In addition, medications, such as nosis and shows how concepts from addiction on 29 September 2021 by guest. Protected copyright. the benwdiazepines, which can be particularly medicine can be integrated with current descrip­ useful and beneficial to one patient, may have tive and criterion-based psychiatric diagnosis (as adverse effects on another. in the Diagnostic and Statisticallvlanual of Mental Physicians need to be knowledgeable about Disorders [DSlvf-III-R)) in the primary care set­ differential treatment outcomes, medication ting. The care of ordinary medical patients can be improved by a clearer understanding of the meaning of symptoms and the ways by which From the Haight Ashbury Training and EduL'ation Project, prescribed or self-medication contributes to the San Francisco; Haight Ashbury Free Clinics, San Francisco; Di­ vision of Alcohol and Drug Abuse, Department of Psychiatry, alleviation or exacerbation of symptoms. University of Maryland School of Medicine, Baltimore; and the Family Medicine Residency Program, Spartanburg Regional Anxiety and Anxiety Disorders Medical Center, Spartanburg, SC. Address reprint requests to Haigbt A~hbury Training and Educdtion Project, 409 Clayton Anxiety disorders are the most common group Street, San FrandsL"O, CA 94117. of psychiatric problems (Robins, et al. reported Anxiety and Substance Abuse Disorders 47 .. --------------------------~.-.-...- ...... J Am Board Fam Pract: first published as 10.3122/jabfm.4.1.47 on 1 January 1991. Downloaded from 8.3 percent of Americans experienced clinically ing, or cold clammy hands; (8) dry mouth; (9) significant anxiety symptoms in a 6-month pe­ dizziness or lightheadedness; (10) nausea, diar­ riod, but only 23 percent received some form of rhea, or other abdominal distress; (11) flushes treatment).! However, the physician's decision to (hot flashes) or chills; (12) frequent urination; treat or how to treat must consider the severity (13) trouble swallowing or "lump in throat." of the problem and the risk-benefit ratio of the • Vigilance and scanning: (14) feeling keyed up treatment selected. Symptoms of anxiety are a or on edge; (15) exaggerated startle response; part of the human experience, but more severe (16) difficulty concentrating or "mind going anxiety creates dysfunction, and treatment deci­ blank" because of anxiety; (17) trouble falling or sions should rest upon an accurate diagnosis. It staying asleep; (18) irritability.4 p 253 is clinically useful to separate anxiety symptoms into two groups: primary and secondary. Substance Use Disorders Primary anxiety includes what patients might Substance use disorders are common in the gen­ refer to as "nervousness." In one large study, 25 eral population and the primary care setting, but percent of Americans considered themselves they are frequently undiagnosed. It is estimated "nervous."! It also includes the symptoms that that between 16 and 18 percent of family prac­ are common elements of many psychiatric dis­ tice patients have a formal diagnosis of alcohol­ orders, as well as such specific anxiety disorders ism. 5-7 Understanding the nomenclature and as generalized anxiety disorder, post-traumatic definitions of addiction medicine can provide an stress disorder, and panic. important diagnostic foothold. There are two Secrmdary anxiety includes symptoms that are particularly useful ways of describing the use of caused by some other primary problem, e.g., psychoactive drugs: drug use patterns and drug medical illness, medications, or drug abuse. The use disorders. physician should consider whether the patient has a neurological problem, endocrine disorder, Drug Use Patterns prescription or street drug problem, alcohol Drug use patterns provide data that can be use­ withdrawal, or is consuming high doses of caf­ ful to form a diagnostic impression related to feine, over-the-counter cold preparations, diet both psychiatric and substance use disorders.8,9 pills, or nicotine. These patterns of volume and frequency of drug It is also important to become familiar with use provide important but incomplete clinical the diagnostic criteria for the various anxiety dis­ descriptions. It is necessary also to understand http://www.jabfm.org/ orders (panic disorder with or without agora­ the distinctions among drug use, abuse, and ad­ phobia, agoraphobia without panic disorder, so­ diction, especially as they apply to prescribed cial phobia, obsessive compulsive disorder, medications and prescription-other drug combi­ post-traumatic stress disorder, and generalized nations. The cornerstone for understanding the anxiety disorder). distinctions among use, abuse, and addiction is The DSM-III-R, for example, describes the the concept of drug-related dysfunction. on 29 September 2021 by guest. Protected copyright. essential feature of generalized anxiety disorder Experimental use is short-term, nonpatterned (GAD) as being unrealistic or excessive anxiety trials of a drug in which the user is motivated and worry about two or more life circumstances chiefly by curiosity and a desire to experience for 6 months or longer, during which the patient the anticipated effect. Such use generally begins has been bothered by these concerns more days socially among friends. than not.4 A minimum of six of the following Social-recreational use occurs in social settings 18 symptoms would be exhibited: among friends or acquaintances who wish to share an experience perceived as acceptable and • Motor tension: (1) trembling, twitching, or pleasurable. The primary motivation is social, feeling shaky; (2) muscle tension, aches, or sore­ and use is voluntary. ness; (3) restlessness; (4) easy fatigability. Circumstantial-situational use' is a self-limited • Autonomic hyperactivity: (5) shortness of use of variable pattern, frequency, intensity, and breath or smothering sensations; (6) palpitations duration. Use is motivated by a perceived need or accelerated heart rate (tachycardia); (7) sweat- to achieve a known drug effect in order to cope 48 JABFP Jan.-Feb.1991 Vol. 4 No.1 1 J Am Board Fam Pract: first published as 10.3122/jabfm.4.1.47 on 1 January 1991. Downloaded from with a specific condition or situation or to en­ current social, occupational, psychologic, or hance the enjoyment of a specific situation. physical problems caused or exacerbated by the Intensified use is long-term patterned use oc­ use of the [drug]." 6 p 169 Alternately, there can curring at least once a day. It is motivated by a be "recurrent use in situations in which use is perceived need or desire to obtain relief from a physically hazardous." As can be seen, drug persistent problem or stressful situation. Use abuse is defined as the use of a psychoactive drug may be unrestrained
Load more

Recommended publications
  • NIDA Monograph 172, Table of Contents
    Treatment of Drug-Dependent Individuals With Comorbid Mental Disorders Editors: Lisa Simon Onken, Ph.D. Jack D. Blaine, M.D. Sander Genser, M.D., M.P.H. and Arthur MacNeill Horton, Jr., Ed.D. NIDA Research Monograph 172 1997 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse Division of Clinical Research 5600 Fishers Lane Rockville, MD 20857 i ACKNOWLEDGMENT This monograph is based on the papers from a technical review on "Comorbid Mental and Addictive Disorders: Treatment and HIV-Related Issues" held on September 27-28, 1994. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder's permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company. Trade, proprietary, or company names appearing in this publication are used only because they are considered essential in the context of the studies reported herein.
    [Show full text]
  • Smoking Cessation Treatment at Substance Abuse Rehabilitation Programs
    SMOKING CEssATION TREATMENT AT SUBSTANCE ABUSE REHABILITATION PROGRAMS Malcolm S. Reid, PhD, New York University School of Medicine, Department of Psychiatry; Jeff Sel- zer, MD, North Shore Long Island Jewish Healthcare System; John Rotrosen, MD, New York University School of Medicine, Department of Psychiatry Cigarette smoking is common among persons with drug and alcohol n Nicotine is a highly use disorders, with prevalence rates of 80-90% among patients in sub- addictive substance stance use disorder treatment programs. Such concurrent smoking may that meets all of produce adverse behavioral and medical problems, and is associated the criteria for drug with greater levels of substance use disorder. dependence. CBehavioral studies indicate that the act of cigarette smoking serves as a cue for drug and alcohol craving, and the active ingredient of cigarettes, nicotine, serves as a primer for drug and alcohol abuse (Sees and Clarke, 1993; Reid et al., 1998). More critically, longitudinal studies have found tobacco use to be the number one cause of preventable death in the United States, and also the single highest contributor to mortality in patients treated for alcoholism (Hurt et al., 1996). Nicotine is a highly addictive substance that meets all of the criteria for drug dependence, and cigarette smoking is an especially effective method for the delivery of nicotine, producing peak brain levels within 15-20 seconds. This rapid drug delivery is one of a number of common properties that cigarette smok- ing shares with hazardous drug and alcohol use, such as the ability to activate the dopamine system in the reward circuitry of the brain.
    [Show full text]
  • Dual Diagnosis and Integrated Treatment of Mental Illnesses and Substance Use Disorders
    Dual Diagnosis and Integrated Treatment of Mental Illnesses and Substance Use Disorders 1919 University Avenue West, Suite 400, St. Paul, MN 55104 Tel. 651-645-2948 or 888-NAMIHELPS www.namihelps.org What are dual diagnosis services? Dual diagnosis services are treatments for people who suffer from co-occurring disorders -- mental illness and substance abuse. Research has strongly indicated that to recover fully, a consumer with co-occurring disorder needs treatment for both problems -- focusing on one does not ensure the other will go away. Dual diagnosis services integrate assistance for each condition, helping people recover from both in one setting, at the same time. Dual diagnosis services include different types of assistance that go beyond standard therapy or medication: assertive outreach, job and housing assistance, family counseling, even money and relationship management. The personalized treatment is viewed as long-term and can be begun at whatever stage of recovery the consumer is in. Positivity, hope and optimism are at the foundation of integrated treatment. How often do people with severe mental illnesses also experience a co-occurring substance abuse problem? There is a lack of information on the numbers of people with co-occurring disorders, but research has shown the disorders are very common. According to reports published in the Journal of the American Medical Association (JAMA): • Roughly 50 percent of individuals with severe mental disorders are affected by substance abuse. • Thirty-seven percent of alcohol abusers and 53 percent of drug abusers also have at least one serious mental illness. • Of all people diagnosed as mentally ill, 29 percent abuse either alcohol or drugs.
    [Show full text]
  • Medications to Treat Opioid Use Disorder Research Report
    Research Report Revised Junio 2018 Medications to Treat Opioid Use Disorder Research Report Table of Contents Medications to Treat Opioid Use Disorder Research Report Overview How do medications to treat opioid use disorder work? How effective are medications to treat opioid use disorder? What are misconceptions about maintenance treatment? What is the treatment need versus the diversion risk for opioid use disorder treatment? What is the impact of medication for opioid use disorder treatment on HIV/HCV outcomes? How is opioid use disorder treated in the criminal justice system? Is medication to treat opioid use disorder available in the military? What treatment is available for pregnant mothers and their babies? How much does opioid treatment cost? Is naloxone accessible? References Page 1 Medications to Treat Opioid Use Disorder Research Report Discusses effective medications used to treat opioid use disorders: methadone, buprenorphine, and naltrexone. Overview An estimated 1.4 million people in the United States had a substance use disorder related to prescription opioids in 2019.1 However, only a fraction of people with prescription opioid use disorders receive tailored treatment (22 percent in 2019).1 Overdose deaths involving prescription opioids more than quadrupled from 1999 through 2016 followed by significant declines reported in both 2018 and 2019.2,3 Besides overdose, consequences of the opioid crisis include a rising incidence of infants born dependent on opioids because their mothers used these substances during pregnancy4,5 and increased spread of infectious diseases, including HIV and hepatitis C (HCV), as was seen in 2015 in southern Indiana.6 Effective prevention and treatment strategies exist for opioid misuse and use disorder but are highly underutilized across the United States.
    [Show full text]
  • Barriers and Solutions to Addressing Tobacco Dependence in Addiction Treatment Programs
    Barriers and Solutions to Addressing Tobacco Dependence in Addiction Treatment Programs Douglas M. Ziedonis, M.D., M.P.H.; Joseph Guydish, Ph.D., M.P.H.; Jill Williams, M.D.; Marc Steinberg, Ph.D.; and Jonathan Foulds, Ph.D. Despite the high prevalence of tobacco use among people with substance use disorders, tobacco dependence is often overlooked in addiction treatment programs. Several studies and a meta-analytic review have concluded that patients who receive tobacco dependence treatment during addiction treatment have better overall substance abuse treatment outcomes compared with those who do not. Barriers that contribute to the lack of attention given to this important problem include staff attitudes about and use of tobacco, lack of adequate staff training to address tobacco use, unfounded fears among treatment staff and administration regarding tobacco policies, and limited tobacco dependence treatment resources. Specific clinical-, program-, and system-level changes are recommended to fully address the problem of tobacco use among alcohol and other drug abuse patients. KEY WORDS: Alcohol and tobacco; alcohol, tobacco, and other drug (ATOD) use, abuse, dependence; addiction care; tobacco dependence; smoking; secondhand smoke; nicotine; nicotine replacement; tobacco dependence screening; tobacco dependence treatment; treatment facility-based prevention; co-treatment; treatment issues; treatment barriers; treatment provider characteristics; treatment staff; staff training; AODD counselor; client counselor interaction; smoking cessation; Tobacco Dependence Program at the University of Medicine and Dentistry of New Jersey obacco dependence is one of to the other. The common genetic vul­ stance use was considered a potential the most common substance use nerability may be located on chromo­ trigger for the primary addiction.
    [Show full text]
  • Dual Diagnosis: SHOW YOU CARE
    or supportive housing. Some people find How to Get Help therapy to be a helpful part of maintaining No insurance? Call the NAMI Southern their sobriety. This can include individual Arizona office to help guide you to access DUAL therapy (e.g., cognitive behavioral therapy) mental health services. as well as self-help groups such as Alcoholics Anonymous, Narcotics If you have dual diagnosis: SHOW YOU CARE. DIAGNOSIS Anonymous or Smart Recovery. Seek medical care through a psychiatrist WEAR A SILVER RIBBON. Certain medications to help maintain and/or your primary care physician. sobriety have been safely tested in multiple studies. For alcoholism, available Find the right combination of treatment Help break down the barriers to FIND HELP. medications include disulfiram (Antabuse), that works for you which may include treatment and support. acamprosate (Campral) and naltrexone medication, therapy, support groups, Help reduce stigma —talk about it! FIND HOPE. (Revia). For opiate abuse, available etc. *Sometimes people must try medications include naltrexone (Revia, several different treatments or combinations of treatment before they Vivitrol), methadone and buprenorphine Mental illness affects 1 in 5 people. We (Subutex, Suboxone). Given how find the one that works for them. provide resources and support to all those complicated these choices may be, it is Take NAMI’s Peer-to-Peer course affected by mental illness. necessary for any individuals with dual and/or join the NAMI Connection diagnosis and their loved ones to discuss support group. NAMI SOUTHERN ARIZONA DEPENDS ON YOU. medication management strategies with their doctors. LEARN about your illness. The more you THERE ARE MANY WAYS TO HELP.
    [Show full text]
  • Cocaine Use Disorder
    COCAINE USE DISORDER ABSTRACT Cocaine addiction is a serious public health problem. Millions of Americans regularly use cocaine, and some develop a substance use disorder. Cocaine is generally not ingested, but toxicity and death from gastrointestinal absorption has been known to occur. Medications that have been used as substitution therapy for the treatment of a cocaine use disorder include amphetamine, bupropion, methylphenidate, and modafinil. While pharmacological interventions can be effective, a recent review of pharmacological therapy for cocaine use indicates that psycho-social efforts are more consistent over medication as a treatment option. Introduction Cocaine is an illicit, addictive drug that is widely used. Cocaine addiction is a serious public health problem that burdens the healthcare system and that can be destructive to individual lives. It is impossible to know with certainty the extent of use but data from public health surveys, morbidity and mortality reports, and healthcare facilities show that there are millions of Americans who regularly take cocaine. Cocaine intoxication is a common cause for emergency room visits, and it is one drug that is most often involved in fatal overdoses. Some cocaine users take the drug occasionally and sporadically but as with every illicit drug there is a percentage of people who develop a substance use disorder. Treatment of a cocaine use disorder involves psycho-social interventions, pharmacotherapy, or a combination of the two. 1 ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com ce4less.com Pharmacology of Cocaine Cocaine is an alkaloid derived from the Erthroxylum coca plant, a plant that is indigenous to South America and several other parts of the world, and is cultivated elsewhere.
    [Show full text]
  • Alcohol Use Disorder
    Section: A B C D E Resources References Alcohol Use Disorder (AUD) Tool This tool is designed to support primary care providers (family physicians and primary care nurse practitioners) in screening, diagnosing and implementing pharmacotherapy treatments for adult patients (>18 years) with Alcohol Use Disorder (AUD). Primary care providers should routinely offer medication for moderate and severe AUD. Pharmacotherapy alone to treat AUD is better than no therapy at all.1 Pharmacotherapy is most effective when combined with non-pharmacotherapy, including behavioural therapy, community reinforcement, motivational enhancement, counselling and/or support groups. 2,3 TABLE OF CONTENTS pg. 1 Section A: Screening for AUD pg. 7 Section D: Non-Pharmacotherapy Options pg. 4 Section B: Diagnosing AUD pg. 8 Section E: Alcohol Withdrawal pg. 5 Section C: Pharmacotherapy Options pg. 9 Resources SECTION A: Screening for AUD All patients should be screened routinely (e.g. annually or when indicators are observed) with a recommended tool like the AUDIT. 2,3 It is important to screen all patients and not just patients eliciting an index of suspicion for AUD, since most persons with AUD are not recognized. 4 Consider screening for AUD when any of the following indicators are observed: • After a recent motor vehicle accident • High blood pressure • Liver disease • Frequent work avoidance (off work slips) • Cardiac arrhythmia • Chronic pain • Rosacea • Insomnia • Social problems • Rhinophyma • Exacerbation of sleep apnea • Legal problems Special Patient Populations A few studies have reviewed AUD in specific patient populations, including youth, older adults and pregnant or breastfeeding patients. The AUDIT screening tool considered these populations in determining the sensitivity of the tool.
    [Show full text]
  • DIAGNOSIS REFERENCE GUIDE A. Diagnostic Criteria for Substance
    ALCOHOL & OTHER DRUG SERVICES DIAGNOSIS REFERENCE GUIDE A. Diagnostic Criteria for Substance Use Disorder See DSM-5 for criteria specific to the drugs identified as primary, secondary or tertiary. P S T (P=Primary, S=Secondary, T=Tertiary) 1. Substance is often taken in larger amounts and/or over a longer period than the patient intended. 2. Persistent attempts or one or more unsuccessful efforts made to cut down or control substance use. 3. A great deal of time is spent in activities necessary to obtain the substance, use the substance, or recover from effects. 4. Craving or strong desire or urge to use the substance 5. Recurrent substance use resulting in a failure to fulfill major role obligations at work, school, or home. 6. Continued substance use despite having persistent or recurrent social or interpersonal problem caused or exacerbated by the effects of the substance. 7. Important social, occupational or recreational activities given up or reduced because of substance use. 8. Recurrent substance use in situations in which it is physically hazardous. 9. Substance use is continued despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by the substance. 10. Tolerance, as defined by either of the following: a. Markedly increased amounts of the substance in order to achieve intoxication or desired effect; Which:__________________________________________ b. Markedly diminished effect with continued use of the same amount; Which:___________________________________________ 11. Withdrawal, as manifested by either of the following: a. The characteristic withdrawal syndrome for the substance; Which:___________________________________________ b.
    [Show full text]
  • Cocaine Intoxication and Hypertension
    THE EMCREG-INTERNATIONAL CONSENSUS PANEL RECOMMENDATIONS Cocaine Intoxication and Hypertension Judd E. Hollander, MD From the Department of Emergency Medicine, University of Pennsylvania, Philadelphia, PA. 0196-0644/$-see front matter Copyright © 2008 by the American College of Emergency Physicians. doi:10.1016/j.annemergmed.2007.11.008 [Ann Emerg Med. 2008;51:S18-S20.] with cocaine intoxication is analogous to that of the patient with hypertension: the treatment should be geared toward the Cocaine toxicity has been reported in virtually all organ patient’s presenting complaint. systems. Many of the adverse effects of cocaine are similar to When the medical history is clear and symptoms are mild, adverse events that can result from either acute hypertensive laboratory evaluation is usually unnecessary. In contrast, if the crisis or chronic effects of hypertension. Recognizing when the patient has severe toxicity, evaluation should be geared toward specific disease requires treatment separate from cocaine toxicity the presenting complaint. Laboratory evaluation may include a is paramount to the treatment of patients with cocaine CBC count; determination of electrolyte, glucose, blood urea intoxication. nitrogen, creatine kinase, and creatinine levels; arterial blood The initial physiologic effect of cocaine on the cardiovascular gas analysis; urinalysis; and cardiac marker determinations. system is a transient bradycardia as a result of stimulation of the Increased creatine kinase level occurs with rhabdomyolysis. vagal nuclei. Tachycardia typically ensues, predominantly from Cardiac markers are increased in myocardial infarction. Cardiac increased central sympathetic stimulation. Cocaine has a troponin I is preferred to identify acute myocardial13 infarction. cardiostimulatory effect through sensitization to epinephrine A chest radiograph should be obtained in patients with and norepinephrine.
    [Show full text]
  • Why Does Smoking So Often Produce Dependence? a Somewhat Diverent View
    62 Tobacco Control 2001;10:62–64 Tob Control: first published as 10.1136/tc.10.1.62 on 1 March 2001. Downloaded from COMMENTARY Why does smoking so often produce dependence? A somewhat diVerent view John R Hughes Abstract These explanations often give little emphasis The usual explanation for why smoking to the possibility that nicotine induces depend- produces dependence focuses on the ence because it produces beneficial eVects that eVects of nicotine on dopamine and other can help smokers cope with their environ- neurobiological explanations. This review ment.89 By beneficial eVects, I mean positive oVers four somewhat diVerent explana- eVects that are not due to relief of withdrawal tions: (1) nicotine can oVer several but rather are eVects above and beyond a “nor- psychopharmacological benefits at the age mal” baseline functioning.10 when such benefits are especially needed; Whether nicotine via smoking causes true (2) cigarettes provide for a rapid, beneficial eVects is, to many, debatable.891112 frequent, reliable and easy-to-obtain My belief (and that of others before me89) that reward; (3) nicotine is not intoxicating, nicotine can cause true beneficial eVects is allowing chronic intake; and (4) the long based on three sets of data. First, nicotine often duration of the nicotine withdrawal causes improvements in animals with no syndrome eVectively undermines cessa- history of nicotine exposure, in never smokers, tion. This article reviews the evidence for and in non-deprived smokers.8911 Second, the above views and the tobacco control most other drugs of dependence produce ben- activities these views suggest. eficial eVects—for example, cocaine produces (Tobacco Control 2001;10:62–64) stimulation and alcohol produces relaxation http://tobaccocontrol.bmj.com/ Keywords: nicotine; substance use disorder; substance and increased confidence.
    [Show full text]
  • Treatment of Patients with Substance Use Disorders Second Edition
    PRACTICE GUIDELINE FOR THE Treatment of Patients With Substance Use Disorders Second Edition WORK GROUP ON SUBSTANCE USE DISORDERS Herbert D. Kleber, M.D., Chair Roger D. Weiss, M.D., Vice-Chair Raymond F. Anton Jr., M.D. To n y P. G e o r ge , M .D . Shelly F. Greenfield, M.D., M.P.H. Thomas R. Kosten, M.D. Charles P. O’Brien, M.D., Ph.D. Bruce J. Rounsaville, M.D. Eric C. Strain, M.D. Douglas M. Ziedonis, M.D. Grace Hennessy, M.D. (Consultant) Hilary Smith Connery, M.D., Ph.D. (Consultant) This practice guideline was approved in December 2005 and published in August 2006. A guideline watch, summarizing significant developments in the scientific literature since publication of this guideline, may be available in the Psychiatric Practice section of the APA web site at www.psych.org. 1 Copyright 2010, American Psychiatric Association. APA makes this practice guideline freely available to promote its dissemination and use; however, copyright protections are enforced in full. No part of this guideline may be reproduced except as permitted under Sections 107 and 108 of U.S. Copyright Act. For permission for reuse, visit APPI Permissions & Licensing Center at http://www.appi.org/CustomerService/Pages/Permissions.aspx. AMERICAN PSYCHIATRIC ASSOCIATION STEERING COMMITTEE ON PRACTICE GUIDELINES John S. McIntyre, M.D., Chair Sara C. Charles, M.D., Vice-Chair Daniel J. Anzia, M.D. Ian A. Cook, M.D. Molly T. Finnerty, M.D. Bradley R. Johnson, M.D. James E. Nininger, M.D. Paul Summergrad, M.D. Sherwyn M.
    [Show full text]